Loading stock data…
TMO
$478.96+12.70 (+2.72%)
Pre-Market$480.00+1.04 (+0.22%)· Last close Apr 30
Thermo Fisher Scientific Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $478.96. The stock is currently 26% below its 52-week high of $643.99, remaining 8.9% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why TMO maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$478.96
Potential Downside
29.4%
Whystock Fair Value$338.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Mean target$620.54+29.6%
Range$520.00 – $750.00
Fundamentals
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four se...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Strong income play. Yield provides a meaningful total return floor.
34.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.33%
Volume
Today's trading volume
1.59M
Recent News
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center
Thermo Fisher Scientific recently opened its flagship U.S. Bioprocess Design Center at its Plainville, Massachusetts site, expanding by 4,000 square feet to offer end-to-end bioproduction workflow support for biologics, vaccines, and cell and gene therapies alongside hands-on customer training. This new center integrates Thermo Fisher’s bioprocess expertise with its existing 290,000-square-foot sterile fill-finish and viral vector facility, reinforcing its role as a comprehensive partner...
Is Corning Stock A Buy At 50 Times Earnings?
Corning (GLW) reported Q1 2026 core sales of $4.35 billion, representing an 18% year-over-year increase. The core insight hiding beneath this headline beat is how entirely the AI-driven acceleration is offsetting the more modest growth currently seen in the company's traditional Glass Innovations segment.
Do You Believe in The Long-Term Growth Outlook of Thermo Fisher Scientific (TMO)?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]
1 Profitable Stock with Impressive Fundamentals and 2 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Thermo Fisher agrees to sell microbiology business to Astorg in $1bn deal
According to GlobalData analyst Dr Andrew S Thompson, the deal signals Thermo Fisher’s move away from the IVD space.